[1]李玉芳,林志烽,项 瑛,等.组蛋白H2A 去泛素化酶BAP1 对恶性胶质瘤细胞发生发展的作用及临床应用价值研究[J].现代检验医学杂志,2024,39(02):7-11+33.[doi:10.3969/j.issn.1671-7414.2024.02.002]
　LI Yufang,LIN Zhifeng,XIANG Ying,et al.Research on the Role and Clinical Application Value of the Histone H2A Deubiquitinase BAP1 in the Occurrence and Progression of Malignant Glioma Cells[J].Journal of Modern Laboratory Medicine,2024,39(02):7-11+33.[doi:10.3969/j.issn.1671-7414.2024.02.002]
点击复制

组蛋白H2A 去泛素化酶BAP1 对恶性胶质瘤细胞发生发展的作用及临床应用价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年02期
页码:
7-11+33
栏目:
论著
出版日期:
2024-03-31

文章信息/Info

Title:
Research on the Role and Clinical Application Value of the Histone H2A Deubiquitinase BAP1 in the Occurrence and Progression of Malignant Glioma Cells
文章编号:
1671-7414（2024）02-007-06
作者:
李玉芳1; 林志烽2; 项 瑛2; 戚 菲2; 韩飞舟3; 钱忠立3; 王 涛4a; 陈 旭4b
（1. 陕西省人民医院放免中心，西安 710068；2. 联勤保障部队大连康复疗养中心，辽宁大连 116013；3. 空军杭州特勤疗养中心，杭州 310007；4. 空军军医大学基础医学院 a. 医学遗传学与发育生物学教研室；b. 生物化学与分子生物学教研室，西安 710032）
Author(s):
LI Yufang1;  LIN Zhifeng2;  XIANG Ying2;  QI Fei2;  HAN Feizhou3;  QIAN Zhongli3;  WANG Tao4a;  CHEN Xu4b
（1. Nuclear Medicine Diagnostic Center, Shaanxi Provincial People’s Hospital, Xi’an 710068, China; 2. Rehabilitation Center of Joint Logistic Force of PLA, Liaoning Dalian 116013, China; 3. Air Force Health Care Center for Special Services, Hangzhou 310007, China; 4a. Department of Medical Genetics and Developmental Biology; 4b. Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Air Force Medical University, Xi’an 710032, China）
关键词:
恶性胶质瘤; 乳腺癌/ 卵巢癌易感基因1 相关蛋白1; 细胞周期; 细胞凋亡; 抑癌基因
分类号:
R730.264；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.02.002
文献标志码:
A
摘要:
目的 探索乳腺癌/ 卵巢癌易感基因1 相关蛋白1（breast/ovarian cancer susceptibility gene 1 associated protein 1，BAP1）对人源恶性胶质瘤发生、发展的作用与BAP1 作为恶性胶质瘤临床诊断标志物的可行性。方法 基于基因表达综合数据库（gene expression omnibus，GEO）的子数据集GSE4290，GSE90598，分析BAP1 在正常组织及胶质瘤组织中的差异性表达情况；受试者工作特征（receiver operating characteristic，ROC）曲线分析BAP1 对恶性胶质瘤的早期诊断价值；选取自主收集的非配对28 例恶性胶质瘤患者的原发灶组织、5 例颅脑外伤患者内减压术切除的非瘤脑组织，采用实时荧光定量PCR（quantitative real-time polymerase chain reaction，qRT-PCR）检测BAP1 的表达水平；利用靶向BAP1 的特异性小干扰RNAs（small interfering RNAs，siRNAs）瞬时转染U251 细胞系，进一步检测其干涉效率；基于流式细胞仪分析BAP1 下调的U251 细胞系，其细胞周期、凋亡的变化情况。结果 生物信息学结果显示， BAP1 在恶性胶质瘤组织中的表达水平均低于正常脑组织（GSE4290：1 209 ± 18.49 vs 1 476 ± 53.90；GSE90598：5.19 ± 0.10vs 5.65 ± 0.21），差异具有统计学意义（t=5.115，2.267，均P<0.05）。ROC 曲线显示，BAP1 可高效区分恶性胶质瘤组织与正常脑组织（GSE4290：AUC=0.78；GSE90598：AUC=0.75，均P<0.05）。临床标本结果显示，BAP1 在恶性胶质瘤原发灶组织中的表达水平显著低于非瘤脑组织（0.27 ± 0.04 vs 1.06 ± 0.07），差异具有统计学意义（t=10.22，P<0.001）。在U251 细胞系中下调BAP1 的表达，其细胞周期中S 期细胞比例明显增多，由17.59 % 分别增至27.21%（siBAP1-1）和25.79%（siBAP1-2），差异具有统计学意义（t=6.576，6.642，均P<0.01），而细胞凋亡水平则有所下降，由10.17 % 分别降至2.70%（siBAP-1）和3.00%（siBAP-2），差异具有统计学意义（t=10.31，9.428，均P<0.01）。结论 组蛋白H2A 去泛素化酶BAP1 能够通过抑制恶性胶质瘤细胞周期快速进展并促进其凋亡，进而发挥肿瘤抑癌基因的功能，可作为潜在的恶性胶质瘤临床诊断标志物。
Abstract:
Objective To explore the role of breast/ovarian cancer susceptibility gene 1 associated protein 1 (BAP1) in the occurrence and progression of human malignant glioma and the feasibility of BAP1 as a clinical diagnostic marker for malignant glioma. Methods The differential expression of BAP1 in normal and glioma tissue was analyzed based on the GSE4290 and GSE90598 sub-datasets from the gene expression omnibus（GEO） database. Receiver operating characteristic (ROC) curve analysis was conducted to assess the early diagnostic value of BAP1 for malignant glioma. Primary lesion tissues from 28 nonpaired malignant glioma patients and non-tumor brain tissues removed by internal decompression surgery in 5 patients with traumatic brain injury collected independently were collected, and the expression levels of BAP1 were measured using quantitative real-time polymerase chain reaction (qRT-PCR). Specific small interfering RNAs (siRNAs) targeting BAP1 were transiently transfected into U251 cells to further evaluate their interference efficiency. Flow cytometry was employed to analyze changes in the cell cycle and apoptosis of U251 cells with BAP1 knockdown. Results The results of bioinformatics showed that the expression of BAP1 in malignant glioma tissues was lower than that in normal brain tissues (GSE 4290: 1 209 ± 18.49 vs 1 476 ± 53.90，GSE 90598: 5.19 ± 0.10 vs 5.65 ± 0.21), and the differences were significant (t=5.115, 2.267, all P<0.05). ROC curve showed that BAP1 could efficiently differentiate malignant glioma tissue from normal brain tissue (GSE4290: AUC=0.78， GSE90598: AUC=0.75, all P<0.05). The expression level of BAP1 in primary malignant glioma tissue was lower than that in normal brain tissue (0.27 ± 0.04 vs 1.06 ± 0.07), and the difference was significant (t=10.22, P<0.001). After down-regulating the expression of BAP1 in U251 cells, the proportion of S phase cells increased from 17.59% to 27.21% (siBAP1-1) and 25.79% (siBAP1-2), respectively, and the differences were significant (t=6.576, 6.642, all P<0.01). However, the apoptosis levels decreased from 10.17% to 2.70% (siBAP-1) and 3.00% (siBAP-2), respectively, and the differences were significant (t=10.31, 9.428, all P<0.01). Conclusion Histone H2A deubiquitinase BAP1 could exert the function of tumor suppressor genes by inhibiting rapid cell cycle progression and promoting apoptosis in malignant glioma, and could serve as a potential clinical diagnostic biomarker for malignant glioma.

参考文献/References:

[1] WANG T J C, MEHTA M P. Low-grade glioma radiotherapy treatment and trials[J]. Neurosurgery Clinics of North America, 2019, 30(1): 111-118.
[2] 秦君翔, 黄锦峰, 袁学刚, 等．miR-124 靶向调控CMTM6 增强CIK 对胶质瘤细胞杀伤效应机制研究[J]．现代检验医学杂志, 2023, 38(1): 94-99． QIN Junxiang, HUANG Jinfeng, YUAN Xuegang,et al. Study on the mechanism of miR-124 targeted regulating of CMTM6 to enhance the cytotoxic effect of CIK on glioma cells[J]. Journal of Modern Laboratory Medicine, 2023, 38(1): 94-99.
[3] MATTIROLI F, PENENGO L. Histone ubiquitination:an integrative signaling platform in genome stability[J].Trends in Genetics, 2021, 37(6): 566-581.
[4] YANG Cong, DING Hongyu, YANG Yang, et al. BAP1 regulates AMPK-mTOR signalling pathway through deubiquitinating and stabilizing tumour-suppressor LKB1[J]. Biochemical and Biophysical Research Communications, 2020, 529(4): 1025-1032.
[5] TSAI Sumei, CHU Kuochang, JIANG Yunjin. Newly identified Gon4l/Udu-interacting proteins implicate novel functions[J]. Scientific Reports, 2020, 10(1):14213.
[6] 刘伶, 邹世芳, 巩亮, 等． 血浆外泌体LncRNABLACAT1 和E-cadherin mRNA 表达水平对乳腺癌早期诊断的价值研究[J]．现代检验医学杂志, 2022,37(5): 70-75． LIU Ling, ZOU Shifang, GONG Liang, et al. Value of plasma exosomes LncRNA BLACAT1 and E-cadherin mRNA expression in early diagnosis of breast cancer[J].Journal of Modern Laboratory Medicine, 2022, 37(5):70-75.
[7] CAMPAGNE A, LEE M K, ZIELINSKI D, et al. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation[J]. Nature Communications, 2019, 10(1): 348.
[8] OKONSKA A, FELLEY-BOSCO E. BAP1 missense mutations in cancer: friend or foe?[J]. Trends in Cancer,2019, 5(11): 659-662.
[9] 吴琼, 郑志存．UBE2T 对肝癌细胞增殖、克隆形成及细胞周期的影响及机制研究[J]．现代检验医学杂志, 2022, 37(2): 115-120, 125． WU Qiong, ZHENG Zhicun. Effects of UBE2T on proliferation, clone formation and cell cycle of hepatocellular carcinoma cells and its molecular mechanism[J]. Journal of Modern Laboratory Medicine,2022, 37(2): 115-120, 125.
[10] 国家卫生健康委员会医政医管局, 中国抗癌协会脑胶质瘤专业委员会, 中国医师协会脑胶质瘤专业委员会. 脑胶质瘤诊疗指南(2022 版)[J]. 中华神经外科杂志, 2022, 38(8): 757-777． Commission of the People’s Republic of China,Medical Administration and Management Bureau,Committee of of China Anti-Cancer Association,Committee of Glioma of Chinese Medical Doctor Association. Guideline for the diagnosis and treatment of glioma (2022 edition)[J]. Chinese Journal of Neurosurgery, 2022, 38(8): 757-777.
[11] WANG L M, ENGLANDER Z K, MILLER M L, et al. Malignant glioma[J]. Advances in Experimental Medicine and Biology, 2023, 1405: 1-30.
[12] 王金湖, 鞠少卿, 王惠民．抑癌基因PTEN 与人类肿瘤的研究进展[J].现代检验医学杂志, 2003, 18 (1):57-59． WANG Jinhu, JU Shaoqing, WANG Huimin. Progress in research on tumor suppressor gene PTEN and human tumor[J]. Journal of Modern Laboratory Medicine,2003, 18(1): 57-59.
[13] LI Jinjian, MENG Qing, ZHOU Xuehui, et al. Gospel of malignant glioma: oncolytic virus therapy[J]. Gene,2022, 818: 146217.
[14] ZHANG Nan, ZHANG Hao, WANG Zeyu, et al. Immune infiltrating cells-derived risk signature based on large-scale analysis defines immune landscape and predicts immunotherapy responses in glioma tumor microenvironment[J]. Frontiers in Immunology, 2021,12: 691811.
[15] WANG Guanyu, WANG Jinpeng, NIU Chaoshi, et al. Neutrophils: new critical regulators of glioma[J].Frontiers in Immunology, 2022, 13: 927233.
[16] DELGADO-L?PEZ P D, CORRALES-GARC?A E M, MARTINO J, et al. Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies[J]. Clinical & Translational Oncology, 2017, 19(8): 931-944.
[17] LI Yuanyuan. Modern epigenetics methods in biological research[J]. Methods, 2021, 187: 104-113.
[18] VILLANUEVA L, ?LVAREZ-ERRICO D, ESTELLER M. The contribution of epigenetics to cancer immunotherapy[ J]. Trends in Immunology, 2020, 41(8): 676-691.
[19] YADAV P, SUBBARAYALU P, MEDINA D, et al. M6A RNA methylation regulates histone ubiquitination to support cancer growth and progression[J]. Cancer Research, 2022, 82(10): 1872-1889.
[20] LI Jiabin, LIANG Jun, TIAN Changlin. Chemical synthesis of di-ubiquitin modified histones for further biochemical studies[J]. Methods in Enzymology, 2020,639: 263-287.
[21] ABDEL-RAHMAN M H, SAMPLE K M, PILARSKI R, et al. Whole exome sequencing identifies candidate genes associated with hereditary predisposition to uveal melanoma[J]. Ophthalmology, 2020, 127(5): 668-678.
[22] HU Z I, MIETTINEN M, QUEZADO M, et al. Meningiomas in patients with malignant pleural mesothelioma harboring germline BAP1 mutations[J].Journal of Thoracic Oncology, 2022, 17(3): 461-466.
[23] DONATI M, MARTINEK P, STEINER P, et al. Novel insights into the BAP1-inactivated melanocytic tumor[J]. Modern Pathology, 2022, 35(5): 664-675.
[24] JAGER M J, SHIELDS C L, CEBULLA C M, et al. Uveal melanoma[J]. Nature Reviews Disease Primers,2020, 6(1): 24.
[25] MASCLEF L, AHMED O, ESTAVOYER B, et al. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression[J]. Cell Death and Differentiation,2021, 28(2): 606-625.
[26] BORU G, GROSEL T W, PILARSKI R, et al. Germline large deletion of BAP1 and decreased expression in non-tumor choroid in uveal melanoma patients with high risk for inherited cancer[J]. Genes Chromosomes & Cancer, 2019, 58(9): 650-656.
[27] LOUIE B H, KURZROCK R. BAP1: not just a BRCA1-associated protein[J]. Cancer Treatment Reviews, 2020, 90: 102091.

备注/Memo

备注/Memo:
基金项目： 国家自然科学基金（81773003）：MYSM1 通过miR-320a/LAMA5 信号抑制结肠癌恶性表型的作用及机制研究；国家自然科
学基金（82203274）：MYSM1 通过调控ITPR1 介导的细胞自噬抑制宫颈癌恶性进展的作用及机制。
作者简介： 李玉芳（1989-），女，硕士，主治医师，主要从事核医学、肿瘤学的研究，E-mail: 757442691@qq.com。
林志烽（1996-），男，本科，医师，主要从事睡眠医学、神经医学、肿瘤表观遗传学调控研究，E-mail: linzhif2021@163.com。为共同第一作者。
通讯作者： 陈旭（1990-），男，博士，主治医师，主要从事肿瘤表观遗传调控研究，E-mail: chenxu_immuno@163.com。
王涛（1976-），男，博士，教授，从事肿瘤发生机制研究，E-mail: wangt@fmmu.edu.cn。为共同通讯作者。
更新日期/Last Update: 2024-03-15